Anavex Life Sciences Corp.

DB:12X1 Stock Report

Market Cap: €741.8m

Anavex Life Sciences Valuation

Is 12X1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 12X1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 12X1 (€8.54) is trading below our estimate of fair value (€613.1)

Significantly Below Fair Value: 12X1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 12X1?

Key metric: As 12X1 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 12X1. This is calculated by dividing 12X1's market cap by their current book value.
What is 12X1's PB Ratio?
PB Ratio6x
BookUS$129.78m
Market CapUS$772.49m

Price to Book Ratio vs Peers

How does 12X1's PB Ratio compare to its peers?

The above table shows the PB ratio for 12X1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.4x31.5%€827.2m
BIO3 Biotest
2x29.3%€1.4b
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
2INV 2invest
1xn/a€63.8m
12X1 Anavex Life Sciences
6x47.7%€772.5m

Price-To-Book vs Peers: 12X1 is expensive based on its Price-To-Book Ratio (6x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 12X1's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
12X1 6.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 12X1 is expensive based on its Price-To-Book Ratio (6x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 12X1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

12X1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 12X1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 12X1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.54
€32.61
+281.7%
33.9%€42.29€13.79n/a4
Nov ’25€6.06
€32.65
+438.8%
33.9%€42.34€13.81n/a4
Oct ’25€4.99
€32.48
+551.1%
33.9%€42.11€13.73n/a4
Sep ’25€5.28
€32.48
+515.5%
33.9%€42.11€13.73n/a4
Aug ’25€6.16
€32.77
+431.7%
33.9%€42.50€13.86n/a4
Jul ’25€3.70
€25.50
+589.3%
45.5%€37.10€13.91n/a2
Jun ’25€3.71
€25.50
+588.2%
45.5%€37.10€13.91n/a2
May ’25€3.30
€30.17
+815.6%
23.1%€37.13€23.21n/a2
Apr ’25€4.68
€30.17
+544.5%
23.1%€37.13€23.21n/a2
Mar ’25€4.64
€30.17
+549.8%
23.1%€37.13€23.21n/a2
Dec ’24€7.02
€42.78
+509.8%
14.9%€49.16€36.41n/a2
Nov ’24€5.21
€44.48
+753.7%
14.9%€51.10€37.85€6.062
Oct ’24€6.35
€44.15
+595.7%
14.9%€50.72€37.57€4.992
Sep ’24€7.26
€43.36
+497.0%
14.9%€49.82€36.90€5.282
Aug ’24€7.46
€43.36
+481.0%
14.9%€49.82€36.90€6.162
Jul ’24€7.26
€43.36
+497.5%
14.9%€49.82€36.90€3.702
Jun ’24€8.74
€43.36
+395.9%
14.9%€49.82€36.90€3.712
May ’24€7.25
€42.73
+489.7%
14.9%€49.10€36.37€3.302
Apr ’24€7.51
€37.49
+399.4%
26.1%€49.78€25.81€4.683
Mar ’24€8.84
€36.71
+315.5%
22.9%€46.67€26.14€4.643
Feb ’24€9.81
€38.38
+291.1%
15.0%€46.05€32.24€5.483
Jan ’24€8.49
€30.56
+260.1%
38.7%€40.11€10.51€8.564
Dec ’23€8.50
€34.55
+306.5%
30.9%€43.64€16.62€7.024
Nov ’23€12.32
€34.55
+180.3%
30.9%€43.64€16.62€5.214

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

5.1%

1Y

22.9%